RVMD Soars on Positive Phase 3 Results and Druckenmiller's Stake

What happened

Revolution Medicines' stock has skyrocketed 125% in 2026, driven by positive Phase 3 data for its lead drug daraxonrasib and news that billionaire Stanley Druckenmiller is loading up on shares. The DeepValue report had earlier rated the stock a Potential Sell at ~$98, citing limited near-term catalysts and a premium valuation, but the Phase 3 success now validates the drug's potential and has attracted high-profile investors. While the positive data reduce the risk of failure, the stock has already surpassed the report's bull case of $130, suggesting much of the upside is priced in. The company still faces significant cash burn and royalty encumbrances that could weigh on future returns. Investors should weigh the validated clinical progress against the stretched valuation and consider taking partial profits.

Implication

The Phase 3 positive data have dramatically improved Revolution's outlook, reducing the binary risk that was central to the earlier bearish thesis. However, the stock's 125% gain has pushed it well above the report's bull case of $130, implying that the market now expects not only approval but also strong commercial performance and potential M&A. The company's $1 billion+ annual cash burn and the royalty obligations to Royalty Pharma will cap per-share value creation even if sales materialize. Druckenmiller's buying adds a positive sentiment tailwind, but it also increases crowdedness and the risk of a sharp pullback if sentiment shifts. For current holders, it's a good time to book partial gains; for new investors, wait for a pullback to a more attractive risk-reward zone, such as near the $100–130 range, where the downside is better protected by the validated pipeline.

Thesis delta

The primary risk of Phase 3 failure has been removed, altering the thesis from a speculative sell to a 'show me' story with high execution risk and a fully priced valuation. The stock has already overshot the original bull case, leaving limited upside without additional catalysts like M&A or superior sales data. The margin of safety has eroded further, making the stock a hold for existing shareholders with a high tolerance for volatility, but less attractive for new entries.